Abstract
Heart failure affects 5.1 million people in the USA annually. It accounts for a frequent cause of hospitalizations and disability. Patients with congestive heart failure have lower plasma levels of CoQ10, which is an independent predictor of mortality in this patient population. It has been hypothesized that a deficiency of CoQ10 can play a role in the development and worsening of heart failure, and that oral supplementation can possibly improve symptoms and survival in these patients. Based on previous small studies and meta-analyses, the use of CoQ10 in heart failure suggested an improvement ejection fraction, stroke volume, cardiac output, and cardiac index with CoQ10 supplementation, however most of these small studies appeared to be underpowered to result in any significant data. The results of the recent Q-SYMBIO trial demonstrated an improvement in heart failure symptoms with a significant reduction in major adverse cardiovascular events and mortality.
Similar content being viewed by others
References
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.
DiNicolantonio J, Bhutani J, McCarty M, O’Keefe J. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart. 2015;2(1):e000326.
Mantle D. Coenzyme Q10 and cardiovascular disease: an overview. October 2015. British J. Cardiology. 2015;22:160.
Kapoor P, Kapoor AK. Coenzyme Q10—a novel molecule. J Indian Acad Clin Med. 2013;14:1.
Folkers K, Littarru GP, Ho L, et al. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch. 1970;40(3):380–90.
Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q 10. Proc Natl Acad Sci U S A. 1985;82:901–4.
Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52:1435–4. Langsjoen, P. Alleviating Congestive Heart Failure with Coenzyme Q10. LE Magazine Febuary 2008.
Rauchova H, Lenaz G, Drahota Z. Function of coenzyme Q in the Cekk: some biochemical and physiological properties. Physiol Res. 1995;44:209–16.
Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;39(6):957–62.
Madmani ME, Yusuf Solaiman A, Tamr Agha K, et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev. 2014;6:CD008684.
Langsjoen P. Alleviating congestive heart failure with coenzyme Q10. LE magazine. 2008.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A. 1985;82(12):4240–4.
Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 1990;12(3):169–71.
Oda T. Effect of coenzyme Q10 on load-induced cardiac dysfunction: double-blind study and investigation of dose-response relationship. In: Lenaz G, Barnabei O, Rabbi A, editors. Highlights in ubiquinone research. Taylor and francis: London; 1990. p. 232–7.
Rossi E, Lombardo A, Testa M, Lippa S, Oradei A, Littarru GP, et al. Coenzyme Q10 in ischaemic cardiopathy. In: Folkers K, Yamagami T, Littarru GP, editors. Biomedical and clinical aspects of coenzyme Q, vol. 6. Amsterdam: Elsevier; 1991. p. 321–6.
Poggesi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy: a medium-term randomized double-blind study versus placebo. Curr Ther Res. 1991;49:878–86.
Rengo F, Abete P, Landino P, et al. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71:S124–S8.
Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q 10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Fail. 1995;1:101–7.
Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors. 1999;9(2-4):285–9.
Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Asp Med. 1994;15:s155–163.
Judy W, Hall J, Toth P, et al. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru G, Yamagami T, editors. Biomedical and clinical aspects of coenzyme Q, vol. 6. Amsterdam: Elsevier, Publishers; 1991. p. 291–8.
Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;65(7):521–3.
Judy W, Hall J, Toth P, et al. Double blind-double crossover study of coenzyme Q10 in heart failure. Biomed Clin Aspects Coenzyme Q. 1986;5:315–23.
VanFraechem JPH, Picalausa C, Folkers K. Ef—fects of CoQ10 on physical performance and recovery in myo- cardial failure. In: Folkers K, Yamamura Y, editors. Biomedical and clinical aspects of coenzyme Q, vol. 5. Amsterdam: Elsevier Publishers; 1986. p. 377.
Schneeberger W, Muller-Steinwachs J, Anda L, et al. A clinical double blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In: Folkers K, Yamamura Y, editors. Biomedical and clinical aspects of coenzyme Q, vol. 5. Amsterdam: Elsevier; 1986. p. 325–33.
Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multi-center randomized study. Clin Investig. 1993;71:S134–6.
Permanetter B, Rössy W, Klein G, Weingartner F, Seidl KF, Blömer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13(11):1528–33.
Watson PS, Scalia GM, Gaibraith AJ, Burstow DJ, Aroney CN, Bett JH. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 2001;175(8):447. author reply 447-8.
Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132(8):636–40.
Soja AM, Mortenson SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18:159–68.
Sander CCI, Patel AA, et al. The impact of coenzyme q10 on systolic function in patients with chronic heart failure. J Card Failure. 2006;12:464–72.
Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr. 2013;97:268–75.
Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G, Kocharian A, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young. 2009;19(5):501–6.
Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145–9.
Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27(5):295–9.
Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation. 2003;12(3):135–41.
2013 ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239
Mortensen S, Kumar A, Filipiak K, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. Eur J Heart Fail. 2013;15(S1):S20.
Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2:641–9.
Langsjoen PHm Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors. 2008;32(1-4):119–28.
Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M. Study on safety and bioavailability of ubiquinol (Kaneka QH (trade mark)) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007;47(1):19–28.
Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273–84.
Mortensen SA. Coenzyme Q10: will this natural substance become a guideline-directed adjunctive therapy in heart failure? JCHF. 2015;3(3):270–1.
Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006;27(22):2675–81.
Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 2007;28(18):2249–55.
Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001;94(11):1112–7.
Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009;4, CD007435.
Caso G et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–12.
Marcoff L, Thompson P. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. JACC. 2007;49(23):2231–7.
Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33(3):226–9.
Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94(10):1306–10.
Our History Timeline. www.Kanekanutrients.com
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Sylvia Oleck and Hector O Ventura have no disclosures.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Pharmacologic Therapy
Rights and permissions
About this article
Cite this article
Oleck, S., Ventura, H.O. Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?. Curr Heart Fail Rep 13, 190–195 (2016). https://doi.org/10.1007/s11897-016-0296-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-016-0296-6